Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + methotrexate + prednisone
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intramuscular
01
Overview
A combination therapy consisting of adalimumab (a TNF-alpha inhibitor), methotrexate (a disease-modifying antirheumatic drug), and prednisone (a corticosteroid). This regimen is primarily used to treat moderate to severe rheumatoid arthritis and other inflammatory conditions. The combination provides complementary mechanisms of action: adalimumab specifically targets TNF-alpha to reduce inflammation, methotrexate affects multiple inflammatory pathways including adenosine signaling, and prednisone provides rapid anti-inflammatory effects while the other medications take effect.
02
Targets
GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on adalimumab + methotrexate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + methotrexate + prednisone.